Acrivon Therapeutics: Buy Rating Reiterated as ACR-2316’s Emerging Clinical Profile and Differentiated Safety Support Unchanged $19 Price Target
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating on Acrivon Therapeutics with a $19 price target. The decision is based on the emerging clinical profile of ACR-2316, which shows meaningful activity in lung and endometrial tumors, and its differentiated safety profile compared to earlier WEE1 inhibitors. The analyst views the trial design and biomarker strategy as strong foundations for late-stage development.
Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Acrivon Therapeutics, Inc., retaining the price target of $19.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Emily Bodnar has given his Buy rating due to a combination of factors, starting with the emerging clinical profile of ACR-2316, which shows meaningful single-agent activity in AP3-selected lung and endometrial tumors at doses of at least 120 mg. The strong disease control rate in heavily pretreated lung cancer patients, coupled with multi-month to year-long treatment durations, suggests that ACR-2316 could ultimately address populations where prior WEE1 inhibitors have underperformed.
Additionally, the safety profile appears differentiated, with manageable hematologic toxicity and an absence of gastrointestinal side effects that have limited earlier WEE1 assets, reinforcing ACR-2316’s competitive potential. Bodnar also views the Project Optimus-aligned trial design and biomarker-driven indication strategy as practical foundations for late-stage development, supporting long-term value creation, and therefore maintains the $19 price target while reiterating a Buy stance on Acrivon’s shares.